The global leukemia therapeutic market is anticipated to grow at a substantial CAGR of 7.3% during the forecast period (2022-2028). According to Cancer.org, the estimated number of new cases registered in 2020 by Acute lymphocytic leukemia was 6,150, chronic lymphocytic leukemia was 21,040, acute myeloid leukemia was 19,940, and chronic myeloid leukemia a new case was 8,450. The major risk factor responsible for the rising number of cancer patients is the consumption of cigarettes, and alcohol other risk factors include type 2 diabetes, excess body weight, and a family history of cancer. With the rise in the number of cancer patients across the globe, the demand for leukemia therapeutics rises in the forthcoming year.
A full report of Leukemia Therapeutic Market is available at: https://www.omrglobal.com/industry-reports/leukemia-therapeutics-market
The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Jazz Pharmaceuticals plc., announced the approval of Rylaze, from US FDA., for the treatment of acute lymphoblastic leukemia(ALL) or lymphoblastic lymphoma (LBL). This drug is specially launched for children who cannot tolerate E. coli-derived asparaginase medicine. In November 2021, Pfizer Inc., announced a collaboration with Trillium Therapeutics, to bring an impressive portfolio that includes biologics that are designed to enhance the ability of patients innate immune system to detect and destroy cancer cells. Its two lead molecules, TTI-622 and TTI-621, block the signal regulatory protein, which is developed as a key immune checkpoint in hematological malignancies.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/leukemia-therapeutics-market
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2021-2028
- Segment Covered- by type, by drugs type
- Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
- Competitive Landscape- are Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb, Cephalon A/S, Daiichi Sankyo, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Novartis, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Leukemia Therapeutic Market– Segmentation
By Type
- Acute myeloid leukemia
- Chronic myeloid leukemia
- Acute lymphocytic leukemia
- Chronic lymphocytic leukemia
By Drugs Type
- Acute Lymphoblastic Leukemia Drugs
- Myelogenous Leukemia Drug
- Chronic Lymphocytic Leukemia Drug
- Acute Promyelocytic Leukemia Drug
- Other Drug
